ACDE Scientific Advisory Board member J. Michael Walsh

J. Michael Walsh, Ph.D.

Dr. Walsh is the President of The Walsh

Group, P.A., a research and consulting firm located in Bethesda, Maryland.  The Walsh

Group specialists provide consulting services and conduct research in substance abuse

policy and technology development.

From 1989-1993, Dr. Walsh served at the White House as the Executive Director of the

President’s Drug Advisory Council in the Executive Office of the President.  He also

acted as the Associate Director of the Office of National Drug Control Policy (ONDCP)

until July 1993.

Prior to his White House appointment (1980-1989), he was Director of the Division of

Applied Research at the National Institute on Drug Abuse (NIDA) in the U.S. Department of

Health and Human Services.  At NIDA, he directed national research programs including

drug policy, drug effects on performance/driving, drug testing, employee assistance

programs, and AIDS treatment research.  Dr. Walsh led the task force that developed

the U.S. Federal Drug Testing Guidelines; he established and directed the National

Laboratory Certification Program and was responsible for coordinating the development of

all Federal Agency drug policies and programs.

Prior to his appointment at NIDA, Dr. Walsh was a civilian scientist at the Naval

Medical Research Institute in Bethesda, Maryland, where from 1966-1980 he conducted

biomedical research examining the effects of drugs on human performance in the areas of

psychopharmacology, behavioral toxicology, and hyperbaric medicine.

Dr. Walsh received his doctoral degree in psychology from the American University in

1973, and is licensed to practice in the State of Maryland.

Dr. Walsh has published more than 70 articles including books, chapters, and research

publications.  He has been an invited speaker at national meetings, appeared on TV

news and commentary (including Nightline, CBS Evening News with Dan Rather, ABC World

News with Peter Jennings, NBC News with Tom Brokaw), and has been a witness before

Congressional committees on both the U.S. Senate and House of Representatives to provide

expert testimony on issues relating to the effects of drugs on performance and safety,

drug testing, laboratory certification, and workplace drug policy.

Back to “ACDE’s Scientific Advisory Board” Page

acdemain.gif (1019 bytes)

Leave a Comment

Your email address will not be published.